CD8A and hepatocellular carcinoma: Thus, R848@M2pep-MPsAFP remarkably boosted anti-PD-1 therapy in HCC, inducing stem-like CD8+ T cell proliferation and differentiation into terminally exhausted CD8+ T cells to exert long-term antitumor effects.